By Fineline Cube 
US-based life sciences giant Thermo Fisher Scientific Inc. (NYSE: TMO) has announced a USD 2 billion investment initiative spanning 2024–2027 to enhance domestic life sciences infrastructure. This strategic move underscores the company’s commitment to expanding its footprint in the US market.
Investment Breakdown
The investment includes USD 1.5 billion in capital expenditures to upgrade and expand US manufacturing operations. Additionally, USD 500 million will be allocated to research and development (R&D) focused on high-impact innovation. This funding will support the advancement of new technologies and solutions in the life sciences sector.
Company Background
Thermo Fisher operates 64 factories across 37 US states, providing a wide range of analytical instruments, specialty diagnostics, and life sciences solutions. The company also offers contract development and manufacturing services for pharmaceutical innovators, solidifying its position as a key player in the industry.-Fineline Info & Tech